McCall Patrick 4

4 · IN8BIO, INC. · Filed Oct 8, 2024

Form 4

Period: 2024-10-04

CHIEF FINANCIAL OFFICER

Transactions

Award
Series C Warrants (right to buy)
2024-10-04+25,316→ 25,316 total
Exercise: $0.27Exp: 2027-10-04→ Common Stock (25,316 underlying)
Award
Common Stock
2024-10-04+25,316→ 52,071 total
Award
Series A Warrants (right to buy)
2024-10-04+20,492→ 20,492 total
Exercise: $0.45Exp: 2025-10-04→ Common Stock (20,492 underlying)
Disposition to Issuer
Series A Warrants (right to buy)
2024-10-04−20,492→ 0 total
Exercise: $1.25Exp: 2025-06-13→ Common Stock (20,492 underlying)

Footnotes (4)

[F1]The reported securities are included within 25,316 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 25,316 shares of common stock.
[F2]The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025.
[F3]Fully vested and exercisable.
[F4]The reported securities are included within 20,492 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock.

Documents

1 file